Developer docs
API playgroundTry for free, no card

Search company profiles

AlmataBio

Full company profile

uuid0023ds9

Namestring
AlmataBio
Websiteurl
almatabio.com
Company typeenum
Private
Founded yearstring
-
Short descriptiontext

AlmataBio is a private, Atlanta-based biotechnology company that, per its firmographic profile, develops an antibody targeting hidradenitis suppurativa and other inflammatory diseases; no operational, pipeline, or financial details are publicly disclosed, and its web domain is currently parked.

Ownership categoryenum
akta.pro rankint
HeadquartersAtlanta, United States
HQ citystring
Atlanta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
antibody therapeutics, inflammatory disease treatment, biopharmaceutical development, hidradenitis suppurativa therapy, monoclonal antibody research
Industry3 codes
1Immunology & Inflammation Pharmaceuticals
CodeHLAIAAADPrimaryYes
2Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
CodeHLAAAIABPrimaryNo
3Gastroenterology & Hepatology Pharmaceuticals
CodeHLAIAAAIPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Therapeutics
No data
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AlmataBio specializes in the development of antibody-based therapeutics aimed at preventing hidradenitis suppurativa and other inflammatory diseases. The company is described as a biopharmaceutical entity focused on antibody discovery and development targeting inflammatory conditions.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Anti-inflammatory antibody therapeutic (hidradenitis suppurativa)
No data
Peers9 records
1ChemoCentryx
TypeEmerging player
Description

Small-cap inflammation biotech with complement pathway antibody programs (acquired by Amgen). Comparable as an emerging inflammation-focused biologic developer with a similar scale profile to a hypothetical AlmataBio.

2Sanofi / Regeneron
TypeBroad incumbent
Description

Dupilumab (Dupixent) is in development for HS and other inflammatory skin diseases. Comparable as a large inflammation antibody developer that competes for the same patient population and prescribers AlmataBio would target.

3UCB
TypeBroad incumbent
Description

Global biopharma with bimekizumab (Bimzelx) approved for HS. Comparable as a large immunology player with a recent HS antibody approval, defining the competitive benchmark for any new HS antibody entrant.

4InflaRx
TypeDirect peer
Description

Biotech focused on anti-inflammatory therapeutics with an HS clinical program (vilobelimab). Comparable as a small-cap inflammation/HS-focused antibody developer pursuing the same indication as AlmataBio.

5Novartis
TypeBroad incumbent
Description

Pharma major with Cosentyx (secukinumab) approved for HS. Comparable as a broad incumbent whose IL-17 antibody franchise sets efficacy expectations for HS antibody programs.

6AbbVie
TypeBroad incumbent
Description

Major immunology incumbent with approved HS therapies (Humira, Skyrizi/Risankizumab). Indirectly comparable as the leading commercial competitor in the hidradenitis suppurativa biologic space that AlmataBio would need to displace or differentiate from.

7MoonLake Immunotherapeutics
TypeDirect peer
Description

Clinical-stage immunology biotech developing sonelokimab, an IL-17A/F nanobody being advanced in hidradenitis suppurativa. Directly comparable to AlmataBio in indication (HS) and modality (antibody-derived biologic for inflammatory disease).

8Arcturus Therapeutics
TypeEmerging player
Description

Smaller-stage biotech developing nucleic acid and protein-based therapies for inflammatory and rare diseases. Comparable in scale and stage to AlmataBio as an emerging inflammation-modality developer.

9Janssen (Johnson & Johnson Innovative Medicine)
TypeBroad incumbent
Description

Develops Tremfya (guselkumab) and other IL-23 antibodies relevant to HS and inflammatory disease. Comparable as a broad incumbent in inflammatory dermatology antibodies.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AlmataBio

Biopharmaceutical Therapeuticsalmatabio.com

AlmataBio is a private, Atlanta-based biotechnology company that, per its firmographic profile, develops an antibody targeting hidradenitis suppurativa and other inflammatory diseases; no operational, pipeline, or financial details are publicly disclosed, and its web domain is currently parked.

AlmataBio firmographics

Firmographics
Name
AlmataBio
Website
https://almatabio.com
Company type
Private
Short description
AlmataBio is a private, Atlanta-based biotechnology company that, per its firmographic profile, develops an antibody targeting hidradenitis suppurativa and other inflammatory diseases; no operational, pipeline, or financial details are publicly disclosed, and its web domain is currently parked.
Ownership category
akta.pro rank

AlmataBio industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
akta.pro secondary industries
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

  • Antibody therapeutics
  • Inflammatory disease treatment
  • Biopharmaceutical development
  • Hidradenitis suppurativa therapy
  • Monoclonal antibody research

Where AlmataBio is headquartered

Location

Headquarters

HQ city
Atlanta
HQ country
United States
HQ region
North America

Markets served

AlmataBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

AlmataBio product offering

Product offering

Core offering

AlmataBio specializes in the development of antibody-based therapeutics aimed at preventing hidradenitis suppurativa and other inflammatory diseases. The company is described as a biopharmaceutical entity focused on antibody discovery and development targeting inflammatory conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Anti-inflammatory antibody therapeutic (hidradenitis suppurativa)

Companies that use AlmataBio

Customer profile

Ideal customer profiles1 record

AlmataBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AlmataBio competitors and assessment

Company assessment

Emerging players

  • ChemoCentryx: Small-cap inflammation biotech with complement pathway antibody programs (acquired by Amgen). Comparable as an emerging inflammation-focused biologic developer with a similar scale profile to a hypothetical AlmataBio.
  • Arcturus Therapeutics: Smaller-stage biotech developing nucleic acid and protein-based therapies for inflammatory and rare diseases. Comparable in scale and stage to AlmataBio as an emerging inflammation-modality developer.

Broad incumbents

  • Sanofi / Regeneron: Dupilumab (Dupixent) is in development for HS and other inflammatory skin diseases. Comparable as a large inflammation antibody developer that competes for the same patient population and prescribers AlmataBio would target.
  • UCB: Global biopharma with bimekizumab (Bimzelx) approved for HS. Comparable as a large immunology player with a recent HS antibody approval, defining the competitive benchmark for any new HS antibody entrant.
  • Novartis: Pharma major with Cosentyx (secukinumab) approved for HS. Comparable as a broad incumbent whose IL-17 antibody franchise sets efficacy expectations for HS antibody programs.
  • AbbVie: Major immunology incumbent with approved HS therapies (Humira, Skyrizi/Risankizumab). Indirectly comparable as the leading commercial competitor in the hidradenitis suppurativa biologic space that AlmataBio would need to displace or differentiate from.
  • Janssen (Johnson & Johnson Innovative Medicine): Develops Tremfya (guselkumab) and other IL-23 antibodies relevant to HS and inflammatory disease. Comparable as a broad incumbent in inflammatory dermatology antibodies.

Direct peers

  • InflaRx: Biotech focused on anti-inflammatory therapeutics with an HS clinical program (vilobelimab). Comparable as a small-cap inflammation/HS-focused antibody developer pursuing the same indication as AlmataBio.
  • MoonLake Immunotherapeutics: Clinical-stage immunology biotech developing sonelokimab, an IL-17A/F nanobody being advanced in hidradenitis suppurativa. Directly comparable to AlmataBio in indication (HS) and modality (antibody-derived biologic for inflammatory disease).

Market position

Customer concentration

AlmataBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AlmataBio leadership team

Management profile

Number of profiles

AlmataBio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AlmataBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AlmataBio

What does AlmataBio do?

AlmataBio specializes in the development of antibody-based therapeutics aimed at preventing hidradenitis suppurativa and other inflammatory diseases. The company is described as a biopharmaceutical entity focused on antibody discovery and development targeting inflammatory conditions.

When was AlmataBio founded?

AlmataBio was founded in -1.

Where is AlmataBio based?

AlmataBio is headquartered in Atlanta, United States, in the North America region.

Who are AlmataBio's main competitors?

Emerging players on record are ChemoCentryx and Arcturus Therapeutics. Broad incumbents are Sanofi / Regeneron, UCB, Novartis, AbbVie and Janssen (Johnson & Johnson Innovative Medicine). Direct peers are InflaRx and MoonLake Immunotherapeutics.

Does AlmataBio have an API?

No public API is recorded for AlmataBio.

What industry is AlmataBio in?

AlmataBio's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AvalotxAvalo Reports 2023 Financial Results and Provides Business UpdatesAvalo Therapeutics announced its 2023 financial results and reported the acquisition of AVTX-009 from AlmataBio, Inc. alongside a private placement financing raising up to $185 million. The company expects this funding to support operations through 2027 while it pursues Phase 2 trials for AVTX-009 in hidradenitis suppurativa, with top-line data expected in 2026.YahooAvalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionAvalo Therapeutics acquired the Phase 2-ready anti-IL-1β monoclonal antibody AVTX-009 from AlmataBio, Inc. Concurrently, Avalo secured up to $185 million in private placement financing led by Commodore Capital and TCGX to fund operations through expected Phase 2 trial results in 2026. The company intends to develop AVTX-009 for hidradenitis suppurativa and other chronic inflammatory indications.GlobeNewswireAvalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionAvalo Therapeutics, Inc. has acquired an anti-IL-1β monoclonal antibody, AVTX-009, from AlmataBio, Inc. and simultaneously announced a private placement financing deal of up to $185 million. This financing includes an initial upfront investment of $115.6 million and aims to extend Avalo's cash runway into 2027, with plans to develop AVTX-009 for hidradenitis suppurativa, expecting Phase 2 trial results in 2026.MarketScreenerAvalo Therapeutics, Inc. acquired AlmataBio, Inc. for $42.5 million.Avalo Therapeutics, Inc. has acquired AlmataBio, Inc. in a transaction valued at $42.5 million. Avalo Therapeutics is a clinical-stage biotechnology company focused on treating immune dysregulation with assets such as AVTX-009.AvalotxAvalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionAvalo Therapeutics acquired AlmataBio, Inc. to obtain the Phase 2-ready anti-IL-1β monoclonal antibody AVTX-009 and concurrently raised up to $185 million through a private placement led by Commodore Capital and TCGX. The funding extends Avalo's cash runway into 2027 to support the development of AVTX-009 for hidradenitis suppurativa, with top-line Phase 2 results expected in 2026. This transaction positions Avalo to advance its lead asset toward clinical trials while securing necessary capital for ongoing operations.